Use of Anticoagulant, and Associated Factors of Anticoagulant Refusal Atrial Fibrillation Patients

Prevalence of Use of Anticoagulant, and Associated Factors of Anticoagulant Refusal in Non-valvular Atrial Fibrillation Patients---- A Study in Hong Kong General Out-patient Clinic

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04062071

Enrollment

300

Registered

2019-08-20

Start date

2019-08-23

Completion date

2020-03-23

Last updated

2019-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

anticoagulants

Brief summary

Atrial fibrillation is a clinically significant cardiac arrhythmia that increases the risk of stroke by 3 to 4 times. Oral anticoagulation has been shown to mitigate stroke risk by two-thirds among patients with AF and is widely recommended in optimizing AF management.Direct oral anticoagulants have also been demonstrated to be superior to warfarin with respect to the risk of fatal bleeding and stroke prevention. However, the previous study finding highlighted a great gap between current guidelines and the clinical management of AF .Nonetheless, the decision for anticoagulant use is not straightforward.It is worth to investigate the updated prevalence of anticoagulant use, the reasons for not receiving anticoagulant, and the factors independently associated with anticoagulant refusal in patients with non-valvular atrial fibrillation.

Interventions

OTHERno intervention

no intervention

Study design

Observational model

ECOLOGIC_OR_COMMUNITY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* diagnosis as atrial fibrillation * aged ≧18 years * able to given consent

Exclusion criteria

* Unable/unwillingness to sign informed consent to study * mechanical heart valve * moderate-to-severe mitral stenosis * Transient atrial fibrillation from reversible cause (e.g., during respiratory tract infection or bronchospasm) * pregnancy * hospitalization within 1 month prior to inclusion in the study.

Design outcomes

Primary

Measure	Time frame	Description
The prevalence of anticoagulant use in non-valvular atrial fibrillation patients	August 2019 to March 2020	calculate the prevalence of anticoagulant use in non-valvular atrial fibrillation patients

Secondary

Measure	Time frame	Description
the rate of the refusal of anticoagulant use	August 2019 to March 2020	calculate the rate of refusal of anticoagulant use in the eligible non-valvular atrial fibrillation patients

Countries

Hong Kong

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026